A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
NCT06319456Phase 3Recruiting
- Lead sponsor
- Ascentage Pharma Group Inc. (Industry)
- Enrollment
- 344 (estimated)
- Start date
- 7 Apr 2024
- Primary completion
- Aug 2027 (estimated)
- Study completion
- 1 Aug 2028
- Last update posted
- 28 Jul 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Lisaftoclax (APG-2575) Drug
- Acalabrutinib Drug
- Fludarabine Drug
- Cyclophosphamide，CTX Drug
- Rituximab Drug
- Chlorambucil Drug
Conditions and primary outcome
- CLL/SLL
Primary outcome
Progress Free Survival (PFS) (Up to 1 year)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06319456.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06319456 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.